托珠单抗 (Actemra, RoActemra, Tyenne +2)

概览

Tocilizumab is an interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).

作用机制

Interleukin 6 (IL-6) is a pro-inflammatory cytokine produced by cells including T-cells, B-cells, lymphocytes, monocytes, fibroblasts. IL-6 rapidly induces C-reactive protein, serum amyloid A, fibrinogen, haptoglobin, and α-1-antichymotrypsin while inhibiting production of fibronectin, albumin, and transferrin. IL-6 also induces antibody production, induces cytotoxic T-cell differentiation, and inhibits regulatory T-cell differentiation. Tocilizumab binds soluble and membrane bound IL-6 receptors, preventing IL-6 mediated inflammation.

适应症

Tocilizumab is indicated to treat moderate to severe rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome. Tocilizumab is also used to treat coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen, mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

• Coronavirus Disease 2019 (COVID‑19)
• Cytokine Release Syndrome caused by CAR-T Cell Therapy
• Giant Cell Arteritis (GCA)
• Juvenile Chronic Polyarthritis
• Moderate to Severe Rheumatoid Arthritis
• Moderately to Severely Active Rheumatoid Arthritis
• Polyarticular Juvenile Idiopathic Arthritis
• Systemic Juvenile Idiopathic Arthritis (SJIA)
• Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
• Active systemic Juvenile idiopathic arthritis
• Severe, active Rheumatoid arthritis